160 related articles for article (PubMed ID: 35526235)
41. Effects of moderate-intensity physical exercise on pharmacokinetics of factor VIII and von Willebrand factor in young adults with severe haemophilia A: a pilot study.
Zourikian N; Merlen C; Bonnefoy A; St-Louis J; Rivard GE
Haemophilia; 2016 May; 22(3):e177-83. PubMed ID: 26988074
[TBL] [Abstract][Full Text] [Related]
42. A comparison of MyPKFiT and WAPPS-Hemo as dosing tools for optimizing prophylaxis in patients with severe haemophilia A treated with Octocog alfa.
Arvanitakis A; Berntorp E; Astermark J
Haemophilia; 2021 May; 27(3):417-424. PubMed ID: 33751755
[TBL] [Abstract][Full Text] [Related]
43. Predicting dose sparing benefit and bleeding risk of pharmacokinetic-based personalized prophylactic dosing of factor VIII products.
Tegenge MA; Yang H; Forshee RA
Haemophilia; 2017 Sep; 23(5):705-711. PubMed ID: 28543946
[TBL] [Abstract][Full Text] [Related]
44. PK-guided personalized prophylaxis with Nuwiq
Lissitchkov T; Rusen L; Georgiev P; Windyga J; Klamroth R; Gercheva L; Nemes L; Tiede A; Bichler J; Knaub S; Belyanskaya L; Walter O; Pasi KJ
Haemophilia; 2017 Sep; 23(5):697-704. PubMed ID: 28452151
[TBL] [Abstract][Full Text] [Related]
45. Association of peak factor VIII levels and area under the curve with bleeding in patients with haemophilia A on every third day pharmacokinetic-guided prophylaxis.
Valentino LA; Pipe SW; Collins PW; Blanchette VS; Berntorp E; Fischer K; Ewenstein BM; Oh M; Spotts G
Haemophilia; 2016 Jul; 22(4):514-20. PubMed ID: 26930418
[TBL] [Abstract][Full Text] [Related]
46. A population pharmacokinetic model for perioperative dosing of factor VIII in hemophilia A patients.
Hazendonk H; Fijnvandraat K; Lock J; Driessens M; van der Meer F; Meijer K; Kruip M; Gorkom BL; Peters M; de Wildt S; Leebeek F; Cnossen M; Mathôt R;
Haematologica; 2016 Oct; 101(10):1159-1169. PubMed ID: 27390359
[TBL] [Abstract][Full Text] [Related]
47. Factor VIII concentrate dosing with lean body mass, ideal body weight and total body weight in overweight and obesity: A randomized, controlled, open-label, 3 × 3 crossover trial.
Seaman CD; Yabes JG; Lalama CM; Ragni MV
Haemophilia; 2021 May; 27(3):351-357. PubMed ID: 33749970
[TBL] [Abstract][Full Text] [Related]
48. Individualized PK-based prophylaxis in severe haemophilia.
Dargaud Y; Delavenne X; Hart DP; Meunier S; Mismetti P
Haemophilia; 2018 Mar; 24 Suppl 2():3-17. PubMed ID: 29543364
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of EC50 of factor VIII as predictor of prophylaxis efficacy in patients with severe haemophilia A.
Fernández-Bello I; Rode F; Álvarez-Román MT; Butta NV; Rivas-Muñoz S; Hernández-Moreno AL; de la Corte-Rodríguez H; Martín-Salces M; Larsen LF; Jiménez-Yuste V
Eur J Pharm Sci; 2019 Feb; 128():215-221. PubMed ID: 30529268
[TBL] [Abstract][Full Text] [Related]
50. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.
Huang K; Zhen Y; Li G; Wu X; Wu R; Chen Z
Haemophilia; 2021 May; 27(3):e340-e346. PubMed ID: 33645868
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetic Modelling to Predict FVIII:C Response to Desmopressin and Its Reproducibility in Nonsevere Haemophilia A Patients.
Schütte LM; van Hest RM; Stoof SCM; Leebeek FWG; Cnossen MH; Kruip MJHA; Mathôt RAA
Thromb Haemost; 2018 Apr; 118(4):621-629. PubMed ID: 29458233
[TBL] [Abstract][Full Text] [Related]
53. Comparison of the Pharmacokinetic Properties of Extended Half-Life and Recombinant Factor VIII Concentrates by In Silico Simulations.
Bukkems LH; Preijers T; van Spengler MWF; Leebeek FWG; Cnossen MH; Mathôt RAA
Thromb Haemost; 2021 Jun; 121(6):731-740. PubMed ID: 33506481
[TBL] [Abstract][Full Text] [Related]
54. Microsimulation to compare activity-related bleed risks between pharmacokinetic-guided rurioctocog alfa pegol prophylaxis and emicizumab.
Sun SX; Crawford S
Expert Rev Hematol; 2023 Mar; 16(3):205-211. PubMed ID: 36655343
[TBL] [Abstract][Full Text] [Related]
55. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia.
Ahnström J; Berntorp E; Lindvall K; Björkman S
Haemophilia; 2004 Nov; 10(6):689-97. PubMed ID: 15569163
[TBL] [Abstract][Full Text] [Related]
56. Predictive performance of pharmacokinetic-guided prophylactic dosing of factor concentrates in hemophilia A and B.
Goedhart TMHJ; Bukkems LH; Zwagemaker AF; Coppens M; Fijnvandraat K; Schols SEM; Schutgens REG; Eikenboom J; Heubel-Moenen FCJI; Ypma PF; Nieuwenhuizen L; Meijer K; Leebeek FWG; Mathôt RAA; Cnossen MH
Res Pract Thromb Haemost; 2024 Mar; 8(3):102397. PubMed ID: 38689619
[TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of Optivate(®), a high-purity concentrate of factor VIII with von Willebrand factor, in patients with severe haemophilia A.
Dmoszynska A; Hellmann A; Baglin T; O'Shaugnessy D; Trelinski J; Kuliczkowski K; Kloczko J; Hay C; Zawilska K; Makris M; Shaikh-Zaidi R; Gascoigne E; Dash C
Haemophilia; 2011 Mar; 17(2):185-90. PubMed ID: 21070496
[TBL] [Abstract][Full Text] [Related]
58. A Novel, Enriched Population Pharmacokinetic Model for Recombinant Factor VIII-Fc Fusion Protein Concentrate in Hemophilia A Patients.
Bukkems LH; Heijdra JM; Mathias M; Collins PW; Hay CRM; Tait RC; Mangles S; Myers B; Evans G; Bailiff B; Curry N; Payne J; Austin S; Goedhart TMHJ; Leebeek FWG; Meijer K; Fijnvandraat K; Chowdary P; Mathôt RAA; Cnossen MH;
Thromb Haemost; 2020 May; 120(5):747-757. PubMed ID: 32369846
[TBL] [Abstract][Full Text] [Related]
59. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A.
Solms A; Shah A; Berntorp E; Tiede A; Iorio A; Linardi C; Ahsman M; Mancuso ME; Zhivkov T; Lissitchkov T
Ann Hematol; 2020 Nov; 99(11):2689-2698. PubMed ID: 32974838
[TBL] [Abstract][Full Text] [Related]
60. Comparison Pharmacokinetic Dosing Tools in Hemophilia A Children.
Genç CA; Gürlek Gökçebay D; Koşan Çulha V; Kaya Z; Özbek NY
Indian J Hematol Blood Transfus; 2024 Jan; 40(1):108-115. PubMed ID: 38312178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
